The H1N1 virus has now become the dominant influenza virus around
the globe, with high levels and an increase of activity in many
regions, the World Health Organization said Thursday.
In a
weekly update, the WHO's point person on the H1N1 virus, Dr. Keiji
Fukuda, also warned the public not to treat the virus like just another
flu.
 |
| The World Health Organization supports the use of vaccines against the H1N1 flu. |
Like seasonal flu, H1N1 is more active in the winter than
in the summer, and a majority of infected people get better on their
own, Fukuda said. H1N1 also is as transmissible and infectious as
seasonal flu, he said.
But unusually for influenza, Fukuda said,
H1N1 continues at high levels over the summer months, and many of the
serious illnesses and deaths are concentrated in people younger than 65.
Seven
months into the pandemic, the virus commonly known as swine flu remains
at high levels and continues to increase in North America, Fukuda said.
Mexico, for example, has seen more cases from September to November
than they saw in the preceding months from April, when the virus
emerged, he said.
The virus is also becoming more active in Europe and Central and Western Asia, Fukuda said.
Health
officials this week reported an outbreak of cases in Ukraine, which now
has more than 250,000 cases of influenza-like illness, with 235
patients requiring intensive care, the WHO said.
Activity is picking up in East Asia, Fukuda said. Mongolia reported "a number" of cases over the past week, he said.
"East Asia is one of the parts of the
world where seasonal influenza viruses have remained in reasonably high
circulation," Fukuda said. "But even in that part of the world, the
pandemic virus is becoming dominant."
More cases are being reported from a number of Caribbean countries such as Cuba and Haiti, he said.
In
Central America and the Southern Hemisphere, however, activity levels
have dropped as those regions enter the summer season, Fukuda said.
"There
are several regions in the world -- North America, Europe, Northern and
Central Asia -- where we are clearly seeing pandemic influenza activity
increase," he said, but "there is no one single place in the world
where we are focused on."
Disease activity has been difficult to predict, Fukuda said.
"We
really are not going to know what the future is going to bring, and so
the main focus of our effort here is ... what steps are needed to make
sure countries are as prepared as possible to deal with disease
levels," he said.
H1N1
poses different challenges in different countries, but it does seem to
be affecting indigenous groups more heavily than nonindigenous groups,
he said.
In Australia, for example, "aboriginal groups are
disproportionately represented in people who end up in hospitals from
diseases related to the pandemic," Fukuda said.
The WHO still
doesn't know whether the effect on indigenous groups is because of the
pandemic itself or because of underlying factors.
Because most
people infected with swine flu tend to recover on their own and don't
suffer major problems afterwards, some people are tempted to dismiss
the infection and think it's not serious. But Fukuda said that's a
dangerous mind-set.
"At WHO, we remain quite concerned about the
patterns we are seeing, particularly because a sizable number of people
develop complications [that lead to death]," he said. "We do see that
the serious complications are concentrated in the younger age groups
rather than the older age groups."
While the complications are
most often seen in people who have chronic, underlying health
conditions and in pregnant women, they also can develop in people "who
are currently healthy and young."
But contrary to some reports, Fukuda said, the WHO
has not seen big mutations in the virus since it first emerged. He said
viruses being isolated now are "generally similar" to those isolated
over the past several months, indicating they haven't changed much.
The
WHO also has no evidence of widespread resistance to antiviral
medication, Fukuda said. There have been sporadic instances of
resistance to oseltamivir -- the generic name for Tamiflu, one of the
main drugs used against influenza -- but such cases are still "isolated
and infrequent," he said.
"Antivirals are quite useful against these infections," he said.
Fukuda
praised as "innovative" the decision by Norway to distribute antiviral
medication over the counter for a limited period of time. The move can
help take stress off the primary health system and allow patients to
get the medicine more quickly, he said.
Other useful protections against H1N1 are vaccines, which the WHO recommends against pandemic infections, Fukuda said.
"These
vaccines now have been used in a significant number of countries ...
and based on this experience, in which millions of people have now
received vaccine, we in fact see that these vaccines are very safe," he
said.
The only side effects are swelling and pain at the
injection site, but "these are occurring at rates that are expected and
usually seen with seasonal influenza vaccine," Fukuda said.
"WHO,
along with other public health authorities, believes that these
vaccines are very useful against pandemic infections and [we] do
support their use," he said.